Tag: Viaskin® Peanut

Viaskin Peanut

DBV to Resubmit Application to FDA for Viaskin Peanut Approval in...

Company allays concerns that BLA would not be resubmitted.
Viaskin Peanut

DBV Withdraws FDA Application for Viaskin Peanut with Plan to Resubmit

The company believes the additional information needed to support this filing is available without further clinical studies.
Peanuts

Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for...

An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.
Viaskin Peanut

DBV Applies for FDA License to Sell Viaskin Peanut Patch Therapy

"This submission represents a significant step forward for those families living with peanut allergy."
Viaskin Patch

Viaskin Peanut Completes Phase III Part A Study of Toddlers With...

Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.
DBV Patch Closeup

Positive Safety Results Reported for Viaskin Peanut Phase III Trial

The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.

Viaskin Peanut Phase III Trial Falls Short, Still Chance for FDA...

The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.
DBV Patch Closeup

DBV Completes Phase III Study of Peanut Patch

The phase III trial was designed to assess the safety and routine clinical use of Viaskin Peanut.
Viaskin Peanut

Peanut Patch Phase III Enrollment Ends, Results Expected Toward End of...

The study received higher-than-expected patient demand.
Packaged Foods

Study: Peanut Immunotherapy Significantly Reduces Risks Due to Cross-Contact in Common...

The study model used common packaged foods such as cookies, ice cream, and doughnuts as references.

Connect with Us

35,946FansLike
94FollowersFollow
285FollowersFollow
2,439FollowersFollow
5,296FollowersFollow
37SubscribersSubscribe